Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806298 | 0.87 | ACHE (0.52) | CYP19A1CYP11B1CYP11B2ACHEALDH1A1 | |
| SCHEMBL28168331 | 0.81 | CYP11B1 (0.52) | CYP19A1CYP11B1CYP11B2ALDH1A1CYP3A4 | |
| SCHEMBL29350013 | 0.81 | MAPT (0.57) | ACHEALDH1A1CYP3A4HPGDL3MBTL1 | |
| SCHEMBL806517 | 0.81 | ACHE (0.54) | ACHEALDH1A1CYP3A4HPGDL3MBTL1 | |
| SCHEMBL13772010 | 0.81 | MAPT (0.57) | ACHEALDH1A1CYP3A4HPGDL3MBTL1 | |
| SCHEMBL13781592 | 0.80 | NCEH1 (0.60) | CYP19A1CYP11B1CYP11B2ALDH1A1L3MBTL1 | |
| SCHEMBL11075536 | 0.80 | CYP11B1 (0.51) | CYP19A1CYP11B1CYP11B2CYP3A4SLC6A2 | |
| SCHEMBL16937930 | 0.78 | NCEH1 (0.39) | CYP19A1CYP11B1CYP11B2ACHEALDH1A1 | |
| SCHEMBL12433142 | 0.78 | MAPT (0.47) | ALDH1A1CYP3A4HPGDL3MBTL1MAPT | |
| SCHEMBL14279013 | 0.78 | CYP19A1 (0.52) | CYP19A1CYP11B1CYP11B2ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-03-15 | — | — | US | disclosed |
| EP-2616460-B1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMA CO LTD (JP) | 2015-10-28 | — | — | EP | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| US-9090572-B2 | Substituted quinoxalines compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-28 | — | — | US | disclosed |
| EP-2570409-B1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT | SHANGHAI INST PHARM INDUSTRY (CN) | 2015-07-08 | — | — | EP | disclosed |
| US-8962621-B2 | Aralkyl diamine derivatives and uses thereof as antidepressants | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2015-02-24 | — | — | US | disclosed |
| EP-2305644-B1 | ARALKYL ALCOHOL PIPERIDINE DERIVATIVE AND THE USE AS MEDICAMENT FOR TREATING DEPRESSION | JIANGSU HENGYI PHARMACEUTICAL CO LTD (CN) | 2014-08-27 | — | — | EP | disclosed |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | OTSUKA PHARMACEUTICAL CO., LTD (JP) | 2013-10-03 | — | — | US | disclosed |
| WO-2013137479-A1 | DECAHYDROQUINOXALINE DERIVATIVES AND ANALOGS THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-09-19 | — | — | WO | disclosed |
| US-20130072488-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-03-21 | — | — | US | disclosed |
| EP-2570409-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT | Shanghai Institute of Pharmaceutical Industry (CN) | 2013-03-20 | — | — | EP | disclosed |
| WO-2012036253-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE. | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-22 | — | — | WO | disclosed |
| WO-2011140998-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANT | 上海医药工业研究院 (CN) | 2011-11-17 | — | — | WO | disclosed |
| US-20110160247-A1 | Aralkyl alcohol piperidine derivative and the use thereof as a medicament for treating depression | JIANGSU GOWORTH INVESTMENT CO. LTD (CN) | 2011-06-30 | — | — | US | disclosed |
| US-20110160247-A1 | Aralkyl alcohol piperidine derivative and the use thereof as a medicament for treating depression | JIANGSU GOWORTH INVESTMENT CO. LTD (CN) | 2011-06-30 | — | — | US | disclosed |
| EP-2305644-A1 | ARALKYL ALCOHOL PIPERIDINE DERIVATIVE AND THE USE AS MEDICAMENT FOR TREATING DEPRESSION THEREOF | Jiangsu Goworth Investment Co. Ltd (CN) | 2011-04-06 | — | — | EP | disclosed |
| US-7576086-B2 | N1-benzyl-N4-(phenylpropane-2-yl-3-ol)piperazine; triple action on hydroxytryptamine (5-HT), noradrenalin (NA)and dopamine(DA); on brain synapses; cytochrome P-450 monooxygenase enzyme system antagonists; enzyme inhibitors; side effect reduction | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2009-08-18 | — | — | US | disclosed |
| US-7332495-B2 | Aralkyl-ketone piperazine derivatives and their uses as new antalgic or ataractic agent | NHWA PHARMA. CORPORATION (CN) | 2008-02-19 | — | — | US | disclosed |
| US-7326710-B2 | Aralkyl formyl-alkyl piperazine derivatives and their uses as a cerebral nerve protective agent | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2008-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072488-A1 | ARALKYL DIAMINE DERIVATIVES AND USES THEREOF AS ANTIDEPRESSANTS | MAOA, SLC6A2, MAOB | CYP19A1 1254/4885CYP11B1 2881/4885CYP11B2 2701/4885 |
| US-11273168-B2 | Methods of treating anxiety by administering a substituted quinolone | CRH, MC2R, HTR3C | CYP19A1 1540/4885CYP11B1 121/4885CYP11B2 88/4885 |
| US-20130261081-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING OR PREVENTING DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREPHNEPHRINE OR DOPAMINE | MC2R, SLC6A2, CRH | CYP19A1 372/4885CYP11B1 101/4885CYP11B2 100/4885 |
| US-20110160247-A1 | Aralkyl alcohol piperidine derivative and the use thereof as a medicament for treating depression | DRD4, DRD5, DRD3 | CYP19A1 3716/4885CYP11B1 2912/4885CYP11B2 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.